STADA brings in Christine Berndt to head specialties and biosimilars business
German drugmaker STADA Arzneimittel (SAZ: Xetra) will from June add to its team by welcoming Dr Christine Berndt as head of global development Specialties/Biosimilars.
Former Sandoz executive Dr Berndt, who joins from MorphoSys (FSE: MOR), takes over from Dr Michael Mack, who is retiring after 18 years of service at STADA.
Dr Berndt, who will also hold the title of vice president, will be based at STADA’s headquarters in Bad Vilbel, Germany, and will report to executive vice president and head of Global Specialties, Bryan Kim. She will be responsible for the development strategy and execution of STADA’s growing specialties and biosimilars portfolio.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze